Market Share Loss Through AI Answer Engines in Pharma

How AI Answer Engines Affect Pharma Market Share and How to Measure the Exposure Patients and healthcare professionals are increasingly asking AI tools about symptoms, diagnoses, and treatment options. Many of these conversations happen outside the channels pharma brands track. When an answer engine recommends a competitor, or omits a therapy that fits the patient, […]

How AI Answer Engines Affect Pharma Market Share and How to Measure the Exposure

Patients and healthcare professionals are increasingly asking AI tools about symptoms, diagnoses, and treatment options. Many of these conversations happen outside the channels pharma brands track. When an answer engine recommends a competitor, or omits a therapy that fits the patient, the effect on market share can be real and difficult to see in standard reporting.

How do we avoid market share loss through large language models?

Avoiding loss starts with diagnosing where and how much your brand is being bypassed, then acting on the root causes with clinical and commercial precision. RED (Recommendation Engine Diagnosis) is designed for this. It identifies the clinical scenarios where your brand is absent or displaced, and provides an MLR-aligned remediation roadmap to address them.

The approach includes:

  • Commercial exposure mapping: identifying the patient scenarios where your brand is bypassed, so the gap can be assessed in commercial terms.
  • Prioritisation framework: scenarios sorted into three tiers: where your brand must be the AI recommendation, where it should appear next, and where it must never appear (off-label or contraindicated).
  • Four remediation levers: Comms Structuring, RAG Source Optimisation, Evidence Gap Resolution, and Scientific Framing, each aimed at a root cause of recommendation gaps.
  • MLR-aligned outputs: recommendations reviewed by medical and scientific professionals so they can move through approval.
  • Longitudinal tracking: optional re-testing to see whether remediation is improving AI recommendation rates over time.

Are AI answer engines causing invisible patient leakage for our brand?

They can. AI answer engines may steer eligible patients toward other options, and this leakage often does not appear in traditional commercial tracking because the conversation happens inside a chatbot rather than a search engine, a clinic, or a sales call.

Identifying leakage involves:

  • Mapping the untracked patient journey: identifying AI-driven journeys that bypass your brand without appearing in existing commercial reporting.
  • Clinical permutation testing: 4,500–15,000+ patient scenarios per indication, to surface recommendation gaps across different patient profiles.
  • Scenario-level diagnosis: determining which patient profiles, defined by age, comorbidity, prior therapy, or symptom presentation, are redirected to competitors.
  • Competitive context: benchmarking your AI visibility against competitors to size the relative risk.
  • A remediation roadmap: an MLR-compliant plan covering medical communications, publication strategy, and AI source optimisation.

How do we identify untracked commercial risk from generative AI in pharma?

Brand teams usually have no direct view of AI-driven clinical queries, because they leave no trace in search analytics, CRM data, or sales force reports. Identifying the risk means testing what AI engines actually say, then translating those results into commercially meaningful terms.

A structured risk assessment includes:

  • Multi-platform exposure mapping: testing representation across ChatGPT, Perplexity, Gemini, Claude, and clinical AI platforms.
  • Quantified gap analysis: converting qualitative representation issues into metrics tied to patient scenarios and therapy eligibility.
  • Competitive benchmarking: identifying where competitors are gaining AI-driven visibility that traditional competitive tracking would miss.
  • An Executive Intelligence Dashboard: findings presented for commercial, brand, and digital leadership to prioritise action.

What commercial exposure are we facing because AI isn’t recommending our treatment?

Estimating the commercial exposure from AI recommendation gaps is one of the more demanding tasks for brand and P&L leaders. A scenario-based audit gives a structured basis for that estimate by linking gaps to defined patient populations and therapy eligibility criteria. Any revenue projection built on this data should be treated as an estimate and validated with your own commercial and forecasting teams.

The analysis typically covers:

  • Scenario-level commercial mapping: linking recommendation gaps to defined patient populations and eligibility criteria.
  • Share of voice analysis: the proportion of AI recommendations going to competitors compared with your brand across all tested scenarios.
  • Line-of-therapy alignment audit: where your therapy is displaced at first-line or second-line decision points.
  • Prioritised remediation: effort focused on the highest-value scenarios first.

The result is a guided strategic engagement, rather than a generic dashboard, that helps leaders decide where to act first.

How is generative AI affecting prescription decisions and our brand’s market share?

Generative AI is increasingly part of how HCPs seek clinical guidance, and the way these tools describe a therapy can influence treatment decisions. Brands that understand their AI representation now are better placed to respond before any effect appears in sales data.

RED examines AI’s influence on prescribing through:

  • HCP query simulation: thousands of realistic HCP-perspective prompts showing how AI describes your therapy during clinical guidance requests.
  • Clinical evidence synthesis audit: whether trial data, endpoints, and label claims are accurately and fairly summarised.
  • Line-of-therapy positioning audit: whether AI places your brand in the correct treatment sequence, or displaces it at key decision points.
  • Multi-platform assessment: coverage of consumer AI tools and specialist clinical AI models increasingly used by HCPs.
  • Longitudinal tracking: monitoring how recommendation patterns shift as new data, publications, or model updates appear.

Where to go next

For the broader strategy, read the guide to AI answer engine optimisation for pharma. To understand how AI representation is measured, read the guide to AI brand visibility audits. For details on the RED engagement, visit the RED product page.

Estimates of commercial exposure depend on the assumptions used and should be validated internally. AI platform outputs vary by query, model version, and time, and an audit does not guarantee future recommendations.

Share this post